Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
6(66.7%)
Phase 3
2(22.2%)
Phase 2
1(11.1%)
9Total
Phase 1(6)
Phase 3(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT02330367Phase 1Unknown

Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC

Role: lead

NCT03878303Phase 1Unknown

Study of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE)

Role: collaborator

NCT03856697Phase 3Unknown

Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation

Role: lead

NCT03300115Phase 2Unknown

Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC

Role: lead

NCT03058094Phase 3Withdrawn

A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI

Role: lead

NCT03053219Phase 1Completed

Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 Treatment

Role: lead

NCT03060850Phase 1Unknown

A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL

Role: lead

NCT03001609Phase 1Completed

Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLC

Role: lead

NCT02274337Phase 1Unknown

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer

Role: collaborator

All 9 trials loaded